aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded on January 1, 2002, Axogen, Inc. is a Florida-based company specializing in the development and distribution of medical instruments for peripheral nerve reconstruction and regeneration. The company's core mission is to restore functionality and sensation to patients suffering from nerve damage. Axogen's product portfolio includes human tissue grafts, nerve connectors, and soft tissue membranes, with its flagship technology being AVANCE, a cell graft that mimics human nerves. The company primarily serves medical professionals and patients experiencing chronic pain or loss of function due to nerve damage.
Axogen is publicly traded on Nasdaq under the ticker AXGN and is a component of the Russell 2000 Index. In 2013, the company successfully raised $18 million through its initial public offering (IPO). Notable achievements include the widespread adoption of its nerve repair solutions in the medical community, significantly impacting patient recovery outcomes. Axogen's innovative approach has positioned it as a leader in the nerve repair industry, contributing to advancements in surgical techniques and improving the quality of life for countless patients.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Medical Instruments
Technology
Biotech
Tags
Healthtech
Model Types
Hardware
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Axogen founded?
Axogen was founded in 2002.
Where is Axogen’s headquarters located?
Axogen’s headquarters is located in DE, US.
When was Axogen’s last funding round?
Axogen’s most recent funding round was for $17.5M (USD) in August 2015.
How many employees does Axogen have?
Axogen has 396 employees as of Feb 6, 2024.
How much has Axogen raised to-date?
As of July 05, 2023, Axogen has raised a total of $90.9M (USD) since Aug 28, 2015.
Add Comparison
Total Raised to Date
$90.9M
USD
Last Update Aug 28, 2015
Last Deal Details
$17.5M
USD
Aug 28, 2015
Post Ipo Equity
Total Employees Over Time
396
As of Feb 2024
Axogen Address
Delaware
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts